In the complex genomic scenario characterizing AML, ddPCR was also used to track DNMT3A, IDH1 and IDH2 mutations: indeed, one third of patients resulted positive for at least one mutation (DNMT3A > IDH2 > IDH1), even in hematological complete remission (CR). This evidence concerns the gene IDH1 and acute myeloid leukemia.